Antiviral drug disposition and natural health products: Risk of therapeutic alteration and resistance

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 6, 2009, Pages 563-578

  MacDonald, Laura ^a   Murty, Mano ^a   Foster, Brian C ^a  

^a HEALTH CANADA   (Canada)

Author keywords

Adverse reactions; Antiretroviral; Herbs; HIV AIDS; Interactions; Natural health products; Resistance; Therapeutic alteration

Indexed keywords

ABACAVIR; ACICLOVIR; ALOE VERA EXTRACT; ALPHA TOCOPHEROL; AMFEBUTAMONE; ANTIRETROVIRUS AGENT; ASCORBIC ACID; ATORVASTATIN; BECLOMETASONE DIPROPIONATE; BICARBONATE; CALCIUM; CARBIDOPA PLUS LEVODOPA; CEFALEXIN; CEFUROXIME AXETIL; CELECOXIB; CHAMOMILE; CHLORAMBUCIL; CITALOPRAM; COLAYUR; CYTOCHROME P450; DEXAMPHETAMINE; DIDANOSINE; DIGOXIN; ECHINACEA EXTRACT; EFAVIRENZ; ENALAPRIL MALEATE; FAMCICLOVIR; FERROUS SULFATE; FLUCONAZOLE; FLUOXETINE; FLUTICASONE PROPIONATE; FLUX O BILE; FOLIC ACID; GARLIC EXTRACT; GARLIPURE; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; LORAZEPAM; MEGESTROL ACETATE; MULTIVITAMIN; NATURAL PRODUCT; NEFAZODONE; NELFINAVIR; NEVIRAPINE; NITROFURANTOIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OLANZAPINE; OMEPRAZOLE; PAROXETINE; PRIMROSE OIL; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 2; RHEUM FRANGULA; RIBAVIRIN; RITONAVIR; ROFECOXIB; SAQUINAVIR; SENNA EXTRACT; SILDENAFIL; SILYBUM MARIANUM EXTRACT; STAVUDINE; SUMATRIPTAN SUCCINATE; TENOFOVIR DISOPROXIL; THERAGRAN; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALGANCICLOVIR; VENLAFAXINE; XYLOMETAZOLINE; Z BEC; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ALFALFA; ANEMIA; AREA UNDER THE CURVE; CHILL; CIRCUMORAL PARESTHESIA; CLINICAL TRIAL; CONCENTRATION LOSS; CREATINE KINASE BLOOD LEVEL; CUSHING SYNDROME; DANDELION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG SUBSTITUTION; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; FEMALE; FEVER; FOOD DRUG INTERACTION; GLYCYRRHIZA; HALLUCINATION; HEART PALPITATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPESTHESIA; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MUSCLE SPASM; NAUSEA; NIGHTMARE; NONHUMAN; PURE RED CELL ANEMIA; RASH; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE DRUG DOSE; TASTE DISORDER; URTICARIA; VOMITING;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL PRODUCTS; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS; PLANTS, MEDICINAL; VITAMINS;

EID: 67649353040     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902942302     Document Type: Review

References (112)

1. Charrois TL, Hill RL, Vu D, et al. Community identification of natural health product-drug interactions. Ann Pharmacother 2007;41:1124-1129 (Pubitemid 47122548)
2. Risa KJ, Nepon L, Justis JC, et al. Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy. Int J STD AIDS 2002;13:706-713
3. Mills E, Montori V, Perri D, et al. Natural health product-HIV drug interactions: a systematic review. Int J STD AIDS 2005;16:181-186 (Pubitemid 40469851)
4. Mills E, Wu P, Ernst E. Complementary therapies for the treatment of HIV: in search of the evidence. Int J STD AIDS 2005;16:395-402 (Pubitemid 40868373)
5. Nutraceutical/Functional food and health claims on food. Health Canada Policy Paper. Ottawa, ON: therapeutic products directorate and food directorate, Health Canada, 2002. Available from: http://www.hc-sc.gc.ca/fn-an/label- etiquet/claims-reclaim/nutra-funct-foods.
6. Draft guidance document for industry reporting adverse reactions to marketed health products. Health Canada Guidance Document. Ottawa, ON: health Canada, marketed health products directorate, 2008. Available from: http://www.hc-sc.gc.ca/dhp-mps/pubs/medeff/-guide/2008-guidance-directrice- reporting-notification/index-eng.php [Last accessed 26 October 2008]
7. Lee LS, Andrade ASA, Flexner C. Interactions between NHPs and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clin Infect Dis 2006;43:1052-1059 (Pubitemid 44631108)
8. Foster BC, Arnason JT, Briggs CJ. Natural health products and drug disposition. Annu Rev Pharmacol Toxicol 2005;45:203-226 (Pubitemid 40261803)
9. ICH E5(R1): Ethnic factors in the acceptability of foreign clinical data. International Conference on Harmonization Guideline. Geneva, SW: International Conference on Harmonization, 1998. Available from: http://www.ich.org/cache/ compo/276-254-1.html [Last accessed 26 October 2008]
10. deMaat MMR, Ekhart GC, Alwin DRH, et al. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003;42(3):223-282
11. g interactions: a systematic review. Int J STD AIDS 2005;16:181-186
12. Hellum BH, Nilsen OG. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 2008;102(5):466-475
13. Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002;32(6):451-478 (Pubitemid 34743619)
14. Izzo AA. Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 2005;19(1):1-16 (Pubitemid 40204343)
15. Pal D, Mitra AK. MDR and CYP3A4-mediated drug-herbal Interactions. Life Sci 2006;78:2131-2145
16. Yang XX, Hu ZP, Duan W, et al. Drug-herb interactions: eliminating toxicity with hard drug design. Curr Pharm Des 2006;12(35):4649-4664 (Pubitemid 44835152)
17. Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005;65(9):1239-1282 (Pubitemid 41038418)
18. Fuhr U. Drug interactions with grapefruit juice; extent, probable mechanism and clinical relevance. Drug Saf 1998;18(4):251-272 (Pubitemid 28177290)
19. Cott JM. Herb-drug interactions: focus on pharmacokinetics. CNS Spectr 2001;6(10):827-832 (Pubitemid 34027305)
20. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004;36(1):57-104 (Pubitemid 38387835)
21. Zhou S, Chan E, Pan SQ, et al. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 2004;18(2):262-276 (Pubitemid 38954916)
22. Izzo AA. Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004;42(3):139-148 (Pubitemid 38647590)
23. Hennessy M, Kelleher D, Spiers JP, et al. St. John's wort increases expression of p-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82 (Pubitemid 34117742)
24. Madabushi R, Frank B, Drewelow B, et al. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 2006;62(3):225-233 (Pubitemid 43357581)
25. Markowitz JS, DeVane CL. The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum). Psychopharmacol Bull 2001;35(1):53-64
26. Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomed 2001;8(2):152-160 (Pubitemid 32267101)
27. Baede-van Dijk PA, van Galen E, Lekkerkerker JF. Drug interactions of Hypericum perforatum (St. John's wort) are potentially hazardous. Ned Tijdschr Geneeskd 2000;144(17):811-812 (Pubitemid 30230124)
28. Brazier NC, Levine MA. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 2003;10(3):163-169
29. Enhanced Post-Marketing Surveillance of HIV/AIDS Drug Therapies- Pilot Project. Phase 1 - Proof of Concept. Version 2.5. Health Canada TPP-BLPA. Ottawa, ON: Health Canada, Therapeutic Products Directorate/Marketed Health Product Directorate; 2000
30. Murty M. Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perpsectives. Can J Physiol Pharmacol 2007;85:952-955 (Pubitemid 350189738)
31. Mueller SO, Stopper H, Dekant W. Biotransformation of the anthraquinones emodin and chrysophanol by P450 enzymes: bioactivation to genotoxic metabolites. Drug Metab Dispos 1998;26(6):540-546 (Pubitemid 28498359)
32. Tang JC, Yang H, Song XY, et al. Inhibition of P450 enzymes by rhein in rat liver microsomes. Phytother Res 2009;23(2):159-164
33. Singh RP, Dhanalakshmi S, Rao AR. Chemomodulatory action of Aloe vera on the profiles of enzymes associated with carcinogen metabolism and antioxidant status regulation in mice. Phytomedicine 2000;7(3):209-219 (Pubitemid 30415079)
34. Ganzera M, Schneider P, Stuppner H. Inhibitory effects of the essential oil of chamomile (Matricaria recutita L) and its major constituents on human P450 enzymes. Life Sci 2006;78(8):856-861 (Pubitemid 43082310)
35. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7(4):273-282 (Pubitemid 30618491)
36. Maliakal PP, Wanwimolruk S. Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol 2001;53(10):1323-1329 (Pubitemid 32982248)
37. Freeman C, Spelman K. A critical evaluation of drug interactions with Echinacea spp. Mol Nutr Food Res 2008;52(7):789-980
38. Foster BC, Drouin C, Krantis A, et al. Chemical marker profile and biological effects of natural products containing Echinacea. J Comp Integr Med 2005;2(1):11
39. Hansen TS, Nilsen OG. Echinacea purpurea and P-glycoprotein drug transport in Caco-2 cells. Phytother Res 2009;23(1):86-91
40. Gurley BJ, Swain A, Williams DK, et al. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008;52(7):772-779
41. Normen L, Yip B, Harris M, et al. Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complication and associations with dyslipidaemia and treatment targets. HIV Med 2007;8:346-356 (Pubitemid 47163266)
42. Laroche M, Choudhri S, Gallicano K, Foster B. Severe gastrointestinal toxicity with concomitant ingestion of ritonavir and garlic. Can J Infect Dis 1998;9(B):471P
43. Foster BC, Foster MS, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001;4(2):176-184 (Pubitemid 34305609)
44. Gallicano K, Foster B, Choudhri S. Effect of short term administration of garlic supplements on single dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmcol 2003;55:199-202 (Pubitemid 36237866)
45. Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234-238 (Pubitemid 34028358)
46. Mohammed Abdul MI, Jiang X, Williams KM, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol 2008;154(8):1691-1700
47. Greenblatt DJ, Leigh-Pemberton RA, von Moltke LL. In vitro interactions of water-soluble garlic components with human cytochromes P450. J Nutr 2006;136(3 Suppl):806S-9S
48. Patel J, Buddha B, Dey S, et al. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in Pgp and CYP3A4 activity. Am J Ther 2004;11(4):262-277
49. Cox MC, Low J, Lee J, et al. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 2006;12(15):4636-4644 (Pubitemid 44297815)
50. Borrelli F, Capasso R, Izzo AA. Garlic (Allium sativum L.): adverse effects and drug interactions in humans. Mol Nutr Food Res 2007;51(11):1386-1397 (Pubitemid 350195612)
51. Huuhka K, Riutta A, Haataja R, et al. The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: a randomized, double-blind, placebo-controlled study. Methods Find Exp Clin Pharmacol 2006;28(7):447-450 (Pubitemid 44568621)
52. Tolonen A, Petsalo A, Turpeinen M, et al. In vitro interaction cocktail assay for nine major P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom 2007;42(7):960-966
53. Granzotto M, Rapozzi V, Decorti G, Giraldi T. Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. J Pineal Res 2001;31(3):206-213 (Pubitemid 32905229)
54. Piscitelli SC, Formentini E, Burstein AH, et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacother 2002;22(5):551-556 (Pubitemid 34464940)
55. DiCenzo R, Shelton M, Jordan K, et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacother 2003;23(7):866-870 (Pubitemid 36875670)
56. Mills E, Wilson K, Clarke M, et al. Milk thistle and indinavir: a randomized controlled pharmacokinetics study. Eur J Clin Pharmacol 2005;61(1):1-7 (Pubitemid 40558272)
57. Mills E, Drouin CE, Arnason JT, Foster BC. Effect of natural health products containing milk thistle on human drug disposition and expression. Int J Naturopath Med 2004;1(1):49-52
58. Budzinski JW, Trudeau VL, Drouin CE, et al. Modulation of human P450 3A4 (CYP3A4) and P-glycoprotein (Pgp) in caco-2 cell monolayers by selected commerical-source milk thistle and goldenseal products. Can J Physiol Pharmacol 2007;85:966-978 (Pubitemid 350189740)
59. Debski B, Milner JA. Dietary selenium supplementation prolongs pentobarbital induced hypnosis. J Nutr Biochem 2004;15(9):548-553 (Pubitemid 39209398)
60. Venhorst J, Rooseboom M, Vermeulen NP, Commandeur JN. Studies on the inhibition of human cytochromes P450 by selenocysteine Se-conjugates. Xenobiotica 2003;33(1):57-72 (Pubitemid 36071763)
61. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St. John's wort. Lancet 2000;355:547-548
62. deMaat MMR, Hoetelmens RMW, Mathot RAA, et al. Drug interaction between St. John's wort and nevirapine. AIDS 2001;15(3):420-421
63. Gurley BJ, Gardner SF, Hubbard MA, et al. Clinical assessment of effects of botanical supplementation on P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005;22(6):525-539 (Pubitemid 41003065)
64. Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with P450. Drug Metab Rev 2003;35(1):35-98
65. Foster BC, Sockovie E, Vandenhoek S, et al. In vitro activity of St. John's wort against cytochrome P450 isozymes and p-glycoprotein. Pharm Biol 2004;42(2):159-169
66. Slain D, Amsden JR, Khakoo RA, et al. Effect of high dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Pharmacother 2005;24(2):165-170 (Pubitemid 40223478)
67. van Heeswijk RP, Cooper CL, Foster BC, et al. Effect of high-dose vitamin C on hepatic P450 3A4 activity. Pharmacother 2005;25(12):1725-1728 (Pubitemid 41790095)
68. Luo G, Guenthner T, Gan LS, Humphreys WG. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 2004;5(6):483-505 (Pubitemid 39534494)
69. Ohyama Y, Yamasaki T. Eight P450s catalyze vitamin D metabolism. Front Biosci 2004;9:3007-3018
70. Jurutka PW, Thompson PD, Whitfield GK, et al. Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of P450 3A4. J Cell Biochem 2005;94(5):917-943 (Pubitemid 41420254)
71. Chan LM, Cooper AE, Dudley AL, et al. P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification. J Drug Target 2004;12(7):405-413 (Pubitemid 39562424)
72. Wang K, Chen S, Xie W, Wan YJ. Retinoids induce P450 3A4 through RXR, VDR-mediated pathway. Biochem Pharmacol 2008;75(11):2204-2213
73. Adedoyin A, Stiff DD, Smith DC, et al. All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes. Cancer Chemother Pharmacol 1998;41(2):133-139 (Pubitemid 28096267)
74. Zhang QY, Dunbar D, Kaminsky L. Human cytochrome P-450 metabolism of retinals to retinoic acids. Drug Metab Dispos 2000;28(3):292-297 (Pubitemid 30137053)
75. Brown L, Heyneke O, Brown D, et al. Impact of traditional medicinal plant extracts on antiretroviral drug absorption. J Ethnopharmacol 2008;119(3):588-592
76. Mehendale S, Aung H, Wang CZ, et al. Scutellaria baicalensis and a constituent flavonoid, baicalein, attenuate ritonavir-induced gastrointestinal side-effects. J Pharm Pharmacol 2007;59(11):1567-1572 (Pubitemid 350057460)
77. Kim H, Kim KB, Ku HY, et al. Identification and characterization of potent CYP2B6 inhibitors in Woohwangcheongsimwon suspension, an herbal preparation used in the treatment and prevention of apoplexy in Korea and China. Drug Metab Dispos 2008;36(6):1010-1015 (Pubitemid 351717457)
78. Beukel van den Bout-van den CJ, Bosch ME, et al. Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications. AIDS 2008;22(10):1243-1244
79. Owen-Smith A, Diclemente R, Wingood G. Complementary and alternative medicine use decreases adherence to HAART in HIV-positive women. AIDS Care 2007;19(5):589-593 (Pubitemid 46763748)
80. Sandhu RS, Precilla RP, Simonelli TM, Edwards DJ. Influence of goldenseal root on the pharmacokintics of indinavir. J Clin Pharmacol 2003;43:1283-1288 (Pubitemid 37280800)
81. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001;61(15):2163-2175 (Pubitemid 34074799)
82. Patel J, Buddha B, Dey S, et al. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in Pgp and CYP3A4 activity. Am J Ther 2004;11(4):262-277
83. Mills E, Wu P, Johnston BC, et al. Natural health product-drug interactions: a systematic review of clinical trials. Ther Drug Monit 2005;27(5):549-557 (Pubitemid 41437629)
84. van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, et al. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev 2006;38(3):477-514 (Pubitemid 44167199)
85. Zhou SF, Zhou ZW, Li CG, et al. Identification of drugs that interact with herbs in drug development. Drug Discov Today 2007;12(15-16):664-673 (Pubitemid 47238642)
86. Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 2005;1(4):629-640
87. Patel IH, Zhang X, Nieforth K, et al. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 2005;44(2):175-186 (Pubitemid 40188939)
88. Staszewski S. Coming therapies: abacavir. Int J Clin Pract Suppl 1999;103:35-38 (Pubitemid 29341328)
89. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008;47(6):351-371 (Pubitemid 351685386)
90. Weiss J, Theile D, Ketabi-Kiyanvash N, et al. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007;35(3):340-344 (Pubitemid 46333919)
91. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004;43(9):595-612 (Pubitemid 38951802)
92. Nekvindová J, Masek V, Veinlichová A, et al. Inhibition of human liver microsomal CYP activities by adefovir and tenofovir. Xenobiotica 2006;36(12):1165-1177 (Pubitemid 44949959)
93. Tong L, Phan TK, Robinson KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007;51(10):3498-3504 (Pubitemid 47519335)
94. Scott LJ, Perry CM. Delavirdine: a review of its use in HIV infection. Drugs 2000;60(6):1411-1444 (Pubitemid 32039394)
95. Tran JQ, Gerber JG, Kerr BM. Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2001;40(3):207-226 (Pubitemid 32324451)
96. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human P450 3A4. Curr Drug Metab 2008;9(4):310-322 (Pubitemid 351836420)
97. Ruiz N. Clinical history of efavirenz. Int J Clin Pract Suppl 1999;103:3-7 (Pubitemid 29341321)
98. Ma Q, Okusanya OO, Smith PF, et al. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol 2005;1(3):473-485
99. Kappelhoff BS, Huitema AD, Mairuhu AT, et al. No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. Anticancer Drugs 2005;16(6):627-630
100. Granfors MT, Wang JS, Kajosaari LI, et al. Differential inhibition of P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 2006;98(1):79-85
101. Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006;45(2):137-168 (Pubitemid 43290828)
102. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005;44(10):1035-1050 (Pubitemid 41356390)
103. Goldsmith DR, Perry CM. Atazanavir. Drugs 2003;63(16):1679-1695
104. Back D, Sekar V, Hoetelmans RM. Darunavir: pharmacokinetics and drug interactions. Antivir Ther 2008;13(1):1-13 (Pubitemid 351541670)
105. Rittweger M, Arastéh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007;46(9):739-756 (Pubitemid 47347446)
106. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63(8):769-802 (Pubitemid 36432083)
107. Dixit V, Hariparsad N, Li F, et al. P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007;35(10):1853-1859 (Pubitemid 47481578)
108. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008;42(7):1048-1059
109. Temesgen Z, Feinberg J. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis 2007;45(6):761-769 (Pubitemid 47381280)
110. Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacother 2007;27(6):888-909 (Pubitemid 46849432)
111. Anker M, Corales RB. Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs 2008;17(1):97-103 (Pubitemid 351578214)
112. Iwamoto M, Kassahun K, Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol 2008;48(2):209-214